Pancreatic Cancer Research

Clinical trialPhase 4Withdrawn

Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

Outcome
Stopped earlySuspended due to Primary Investigator's decision (Other)
Phase
Phase 4
Status
Withdrawn
Study type
Interventional
Planned start
25 June 2019
Planned end
1 June 2020
Enrollment
0 participants
Sites
1
Primary outcomes
Change in immune activation in pancreatic tumor tissue following treatment with antibiotics and pembrolizumab measured by activation of HLA-DR,; Change in immune activation in pancreatic tumor tissue following treatment with antibiotics and pembrolizumab measured by activation of
Sponsor type
Academic / other
Results posted
No
Last update
26 June 2020

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

A multi-institutional, single arm pilot study of antibiotics and pembrolizumab for the treatment of surgically resectable pancreatic cancer. The primary purpose of this study is to determine the change in immune activation in pancreatic tumor tissue following treatment with antibiotics and pembrolizumab.